Learn about the indications for FEIBA.

PROOF Study: FEIBA is clinically effective for prophylaxis1

The PROOF Study demonstrated that FEIBA prophylaxis resulted in a significant reduction in annual bleed rates (ABRs) for joint bleeds and target joint bleeds. FEIBA prophylaxis also showed a trend towards reducing the development of new target joints (ns).1* The authors also suggest that prophylaxis could prevent repeated joint bleeding—a promising hypothesis for patients who start primary prophylaxis at an early age.1
Read more

Guidelines for the Management of Haemophilia

Access haemophilia treatment guidelines and protocols outlined by the World Federation of Hemophilia. Full article

Suggestions for the Management of Factor VIII Inhibitors

View recommendations from the World Federation of Hemophilia on practical approaches to treating patients with Factor VIII inhibitors. Full article

Bringing About Personalised Innovation in Haemophilia Treatment

With more than 50 years of commitment to innovating haemophilia care, Shire understands the challenges facing the community and individual patients. Shire is investing in research and development programs to address patient needs and create optimal personalised solutions to help improve the everyday lives of people with haemophilia and other bleeding disorders. Read more

Explore FEIBA case studies

Important Safety Information

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

  • Hypersensitivity to the product or any of the components.
  • Disseminated Intravascular Coagulation (DIC).
  • Acute thrombosis or embolism (including myocardial infarction).

Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke have occurred in the course of treatment with FEIBA, particularly after administration of doses above the maximum daily dose and/or prolonged application or in patients with other risk factors for thromboembolic events.
As with any intravenously administered plasma product, allergic type hypersensitivity reactions may occur; patients should be informed of the early signs of hypersensitivity reactions. When medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.
Administration of FEIBA to patients with inhibitors may result in an initial anamnestic rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time. Clinical and published data suggest that the efficacy of FEIBA is not reduced.

Notation

* ns = not significant.
Defined as ≥ 4 haemarthroses in a single joint during a 6-month study period.

References

  1. 1. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [published online ahead of print August 1, 2013]. Haemophilia. 2014;20(1):65-72. DOI:10.1111/hae.12246.
  2. 2. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365:1684-1692.